5-Fluoro-AMT

Use and effects

5-Fluoro-AMT has been said to be psychoactive in humans at a dose of 25mg orally, although the qualitative nature of these effects has not been well-described. Preclinical studies suggest that 5-fluoro-αMT may be a psychedelic, stimulant, and/or entactogen in humans. However, 5-fluoro-AMT may be dangerous in humans due to its concomitant potent monoamine oxidase inhibition.

William Leonard Pickard has described his experiences with 5-fluoro-AMT, which he had synthesized along with 6-fluoro-AMT, in personal interviews. According to Pickard, 5-fluoro-AMT had a duration of at minimum 9hours and varied in length significantly. The dose was 25mg and above. Pickard has said that 5-fluoro-AMT was not a "warm drug" but that he remained favorable to it. Its effects included time dilation among others. He said that it gave him the worst post-trip headaches he'd experienced from any psychedelic and they lasted up to 24hours.

Pickard has said that 5-fluoro-AMT is less potent and long-lasting than 6-fluoro-AMT. The related drug AMT was one of Pickard's favorite psychedelics, and he said that he took it more than 50times and experienced no negative side effects with it.

Interactions

Pharmacology

Pharmacodynamics

5-Fluoro-AMT has been found to act as a fairly balanced serotonin-norepinephrine-dopamine releasing agent (SNDRA), as a serotonin 5-HT2A receptor agonist, and as a potent and specific MAO-A inhibitor. Its values in terms of monoamine release are 14 to 19nM for serotonin, 78 to 126nM for norepinephrine, and 32 to 37nM for dopamine in rat brain synaptosomes. The drug's EC50 at the serotonin 5-HT2A receptor is 8.47nM and its at the receptor is 107%. The of 5-fluoro-AMT for MAO-A is 180 to 450nM. This is similar to the potency of αMT, para-methoxyamphetamine (PMA), and 4-methylthioamphetamine (4-MTA).

5-Fluoro-αMT induces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents. It is also known to reverse reserpine-induced behavioral depression, suggesting that it has antidepressant- or stimulant-like effects as well. 5-Fluoro-AMT does not substitute for cocaine in drug discrimination tests but did substitute for cocaine in monkeys. It does not facilitate intracranial self-stimulation (ICSS) in rodents.

Chemistry

Analogues

Analogues of 5-fluoro-AMT include 5-fluorotryptamine, 5-fluoro-DMT, 5-fluoro-AET, and BK-5F-NM-AMT, as well as 5-chloro-αMT, 6-fluoro-AMT, 7-chloro-AMT, 7-methyl-αET, 5-API (PAL-571), and flucindole, among others.

BK-5F-NM-AMT, the N-methyl and β-keto derivative of 5-fluoro-AMT, is a serotonin–dopamine releasing agent (SDRA) analogously to 5-fluoro-AMT. In contrast to 5-fluoro-AMT and many other tryptamines however, BK-5F-NM-AMT is inactive as an agonist of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors and is inactive as a monoamine oxidase inhibitor (MAOI).

History

5-Fluoro-AMT was first described in the scientific literature, by Asher Kalir and Stephen Szara, by 1963, and was described as showing antidepressant- or stimulant-like effects in rodents. It was first tried in humans by 1984. The drug's psychedelic-like effects in animals were described by 1995. 5-Fluoro-AMT's monoamine release and serotonin receptor agonism were shown by 2014, along with support for it having stimulant-like effects in monkeys. The drug was investigated as a possible candidate for treatment of cocaine dependence and these findings were published in 2014.

Society and culture

Legal status

Canada

5-Fluoro-AMT is not an explicitly nor implicitly controlled substance in Canada as of 2025.

United States

5-Fluoro-AMT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

References

References

1. (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology (Berl).
2. (June 2014). "Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys". Experimental and Clinical Psychopharmacology.
3. (11 November 2024). "5-Fluoro-AMT".
4. (1984). "Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview". J Psychoactive Drugs.
5. (2019). "Amphetamine Derivatives as Monoamine Oxidase Inhibitors". Front Pharmacol.
6. "Unusual Analogues: Drugs Used by Gordon Todd Skinner". This Land Press.
7. (March 1998). "Effect of gamma-mangostin through the inhibition of 5-hydroxy-tryptamine2A receptors in 5-fluoro-alpha-methyltryptamine-induced head-twitch responses of mice". British Journal of Pharmacology.
8. (April 2017). "In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks". Toxicol Lett.
9. (October 1986). "Selective inhibition of monoamine oxidase A and B by two substrate-analogues, 5-fluoro-alpha-methyltryptamine and p-chloro-beta-methylphenethylamine". Research Communications in Chemical Pathology and Pharmacology.
10. (April 1991). "Inhibition of monoamine oxidase by two substrate-analogues, with different preferences for 5-hydroxytryptamine neurons". Neuropharmacology.
11. (1967). "A possible correlation between drug-induced hallucinations in man and a behavioural response in mice". Psychopharmacologia.
12. (January 1981). "The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs". Pharmacology, Biochemistry, and Behavior.
13. (October 2014). "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorg Med Chem Lett.
14. (January 2004). "Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives". Neurotoxicology.
15. (2018). "Behavioral Neurobiology of Psychedelic Drugs".
16. (February 1995). "alpha-Methylated tryptamine derivatives induce a 5-HT receptor-mediated head-twitch response in mice". Neuropharmacology.
17. (November 1963). "Synthesis and Pharmacological Activity of Fluorinated Tryptamine Derivatives". J Med Chem.
18. "Advantageous tryptamine compositions for mental disorders or enhancement".
19. (5 December 2025). "Controlled Drugs and Substances Act".
20. (January 2026). "Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)". U.S. [[Department of Justice]]: [[Drug Enforcement Administration]] (DEA): Diversion Control Division.